Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y, Takeuchi M, Makita Z.
Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease.Brain Res.
2001 Jan 12;888(2):256-262.
'Exploration of the ... mutation of the alpha-synuclein gene as that in familial PD (Ala53Thr) ... in sporadic PD, DLB, and AD revealed the mutation in none of the samples of 329 cases and 230 controls examined, suggesting that this mutation is not involved in these neurological diseases.'
REAGENTS/MATERIAL: Tissue sampling and staining
anti-phosphorylated tau mAb AT8 (Innogenetic, dilution of 1:3000)
anti-human beta-amyloid mAb 6F/3D (Dako, dilution of 1:100)
rabbit anti-ubiquitin antibody (Dako, dilution of 1:100)
Quantitation and Distribution of SPs and NFTs
Neocortical SPs were identified by Bodian staining, NFTs and NTs were evaluated and classified based on Braak and Braak staging of neurofibrillary changes of AD.
LB509 mAb, raised against purified LBs specifically from DLB brains, recognizes aa 115-122, dilution of 1:50
#17 polyclonal Ab, raised against a synthetic peptide corresponding to aa 1-10 of human alpha-synuclein, dilution of 1:1000
FUTURE DIRECTION: Study the ineraction between tau and alpha-synuclein to determine the mechanism of non-LB-type alpha-synuclein aggregation. Study the whether LB formation influence the degree of tau aggregation.